APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Acting Antivirals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Direct Acting Antivirals Market Outlook and Growth Opportunities 2026

27 December 2025190 pages

Choose your research edition.

Industry ResearchDirect Acting Antivirals Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Acting Antivirals Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Direct Acting Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Acting Antivirals Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Acting Antivirals Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Direct Acting Antivirals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Direct Acting Antivirals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Direct Acting Antivirals market include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Direct Acting Antivirals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Direct Acting Antivirals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Direct Acting Antivirals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Direct Acting Antivirals market size, projected growth trends, production technologies, key applications, and end-use industries.

Direct Acting Antivirals Segment by Company

AbbVie

Asegua Therapeutics

Bristol Myers Squibb

Gilead Sciences

Merck

Ascletis Pharma

Cosunter pharmaceutical

Kawin Technology

Sanhome Pharmaceutical

Beijing Sihuan Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Direct Acting Antivirals Segment by Type

Pangenotypic

Genotype-Specific

Direct Acting Antivirals Segment by Application

Hospital and Clinic

Pharmacy

Other

Direct Acting Antivirals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Direct Acting Antivirals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Direct Acting Antivirals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Direct Acting Antivirals significant trends, drivers, influence factors in global and regions.

6. To analyze Direct Acting Antivirals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Acting Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Acting Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Acting Antivirals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Acting Antivirals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Direct Acting Antivirals industry.

Chapter 3: Detailed analysis of Direct Acting Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Direct Acting Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Direct Acting Antivirals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Direct Acting Antivirals Industry Trends Table 2. Direct Acting Antivirals Industry Drivers Table 3. Direct Acting Antivirals Industry Opportunities and Challenges Table 4. Direct Acting Antivirals Industry Restraints Table 5. Global Direct Acting Antivirals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Direct Acting Antivirals Revenue Share by Company (2021-2026) Table 7. Global Direct Acting Antivirals Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Direct Acting Antivirals Sales Volume Share by Company (2021-2026) Table 9. Global Direct Acting Antivirals Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Direct Acting Antivirals Company Ranking, (2024-2026) & (USD Million) Table 11. Global Direct Acting Antivirals Key Company Manufacturing Base & Headquarters Table 12. Global Direct Acting Antivirals Company, Product Type & Application Table 13. Global Direct Acting Antivirals Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Direct Acting Antivirals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pangenotypic Table 18. Significant Companies of Genotype-Specific Table 19. Global Direct Acting Antivirals Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Direct Acting Antivirals Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Direct Acting Antivirals Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Direct Acting Antivirals Sales Volume Share by Type (2021-2026) Table 23. Global Direct Acting Antivirals Sales Volume Share by Type (2027-2032) Table 24. Global Direct Acting Antivirals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Direct Acting Antivirals Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Direct Acting Antivirals Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Direct Acting Antivirals Sales Value Share by Type (2021-2026) Table 28. Global Direct Acting Antivirals Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Direct Acting Antivirals Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Direct Acting Antivirals Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Direct Acting Antivirals Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Direct Acting Antivirals Sales Volume Share by Application (2021-2026) Table 36. Global Direct Acting Antivirals Sales Volume Share by Application (2027-2032) Table 37. Global Direct Acting Antivirals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Direct Acting Antivirals Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Direct Acting Antivirals Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Direct Acting Antivirals Sales Value Share by Application (2021-2026) Table 41. Global Direct Acting Antivirals Sales Value Share by Application (2027-2032) Table 42. Global Direct Acting Antivirals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Direct Acting Antivirals Sales by Region (2021-2026) & (K Units) Table 44. Global Direct Acting Antivirals Sales Market Share by Region (2021-2026) Table 45. Global Direct Acting Antivirals Sales by Region (2027-2032) & (K Units) Table 46. Global Direct Acting Antivirals Sales Market Share by Region (2027-2032) Table 47. Global Direct Acting Antivirals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Direct Acting Antivirals Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Direct Acting Antivirals Sales Value Share by Region (2021-2026) Table 50. Global Direct Acting Antivirals Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Direct Acting Antivirals Sales Value Share by Region (2027-2032) Table 52. Global Direct Acting Antivirals Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Direct Acting Antivirals Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Direct Acting Antivirals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Direct Acting Antivirals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Direct Acting Antivirals Sales by Country (2021-2026) & (K Units) Table 57. Global Direct Acting Antivirals Sales Market Share by Country (2021-2026) Table 58. Global Direct Acting Antivirals Sales by Country (2027-2032) & (K Units) Table 59. Global Direct Acting Antivirals Sales Market Share by Country (2027-2032) Table 60. Global Direct Acting Antivirals Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Direct Acting Antivirals Sales Value Market Share by Country (2021-2026) Table 62. Global Direct Acting Antivirals Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Direct Acting Antivirals Sales Value Market Share by Country (2027-2032) Table 64. AbbVie Company Information Table 65. AbbVie Business Overview Table 66. AbbVie Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. AbbVie Direct Acting Antivirals Product Portfolio Table 68. AbbVie Recent Development Table 69. Asegua Therapeutics Company Information Table 70. Asegua Therapeutics Business Overview Table 71. Asegua Therapeutics Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Asegua Therapeutics Direct Acting Antivirals Product Portfolio Table 73. Asegua Therapeutics Recent Development Table 74. Bristol Myers Squibb Company Information Table 75. Bristol Myers Squibb Business Overview Table 76. Bristol Myers Squibb Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Bristol Myers Squibb Direct Acting Antivirals Product Portfolio Table 78. Bristol Myers Squibb Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Gilead Sciences Direct Acting Antivirals Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. Merck Company Information Table 85. Merck Business Overview Table 86. Merck Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck Direct Acting Antivirals Product Portfolio Table 88. Merck Recent Development Table 89. Ascletis Pharma Company Information Table 90. Ascletis Pharma Business Overview Table 91. Ascletis Pharma Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Ascletis Pharma Direct Acting Antivirals Product Portfolio Table 93. Ascletis Pharma Recent Development Table 94. Cosunter pharmaceutical Company Information Table 95. Cosunter pharmaceutical Business Overview Table 96. Cosunter pharmaceutical Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio Table 98. Cosunter pharmaceutical Recent Development Table 99. Kawin Technology Company Information Table 100. Kawin Technology Business Overview Table 101. Kawin Technology Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Kawin Technology Direct Acting Antivirals Product Portfolio Table 103. Kawin Technology Recent Development Table 104. Sanhome Pharmaceutical Company Information Table 105. Sanhome Pharmaceutical Business Overview Table 106. Sanhome Pharmaceutical Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio Table 108. Sanhome Pharmaceutical Recent Development Table 109. Beijing Sihuan Pharmaceutical Company Information Table 110. Beijing Sihuan Pharmaceutical Business Overview Table 111. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio Table 113. Beijing Sihuan Pharmaceutical Recent Development Table 114. YiChang HEC ChangJiang Pharmaceutical Company Information Table 115. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 116. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio Table 118. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 119. Chia Tai Tianqing Pharmaceutical Company Information Table 120. Chia Tai Tianqing Pharmaceutical Business Overview Table 121. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio Table 123. Chia Tai Tianqing Pharmaceutical Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Direct Acting Antivirals Distributors List Table 127. Direct Acting Antivirals Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Direct Acting Antivirals Product Image Figure 2. Global Direct Acting Antivirals Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Acting Antivirals Sales Value (2021-2032) & (US$ Million) Figure 4. Global Direct Acting Antivirals Sales (2021-2032) & (K Units) Figure 5. Global Direct Acting Antivirals Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Direct Acting Antivirals Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pangenotypic Image Figure 10. Genotype-Specific Image Figure 11. Global Direct Acting Antivirals Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Direct Acting Antivirals Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Direct Acting Antivirals Sales Volume Share by Type (2021-2032) Figure 14. Global Direct Acting Antivirals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Direct Acting Antivirals Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Direct Acting Antivirals Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Direct Acting Antivirals Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Direct Acting Antivirals Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Direct Acting Antivirals Sales Volume Share by Application (2021-2032) Figure 23. Global Direct Acting Antivirals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Direct Acting Antivirals Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Direct Acting Antivirals Sales Value Share by Application (2021-2032) Figure 26. Global Direct Acting Antivirals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Direct Acting Antivirals Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Direct Acting Antivirals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Direct Acting Antivirals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Direct Acting Antivirals Sales Value (2021-2032) & (US$ Million) Figure 31. North America Direct Acting Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Direct Acting Antivirals Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Direct Acting Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Direct Acting Antivirals Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Direct Acting Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Direct Acting Antivirals Sales Value (2021-2032) & (US$ Million) Figure 37. South America Direct Acting Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Direct Acting Antivirals Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Direct Acting Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Direct Acting Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Direct Acting Antivirals Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Direct Acting Antivirals Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Pangenotypic
  • Genotype-Specific
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • AbbVie
  • Asegua Therapeutics
  • Bristol Myers Squibb
  • Gilead Sciences
  • Merck
  • Ascletis Pharma
  • Cosunter pharmaceutical
  • Kawin Technology
  • Sanhome Pharmaceutical
  • Beijing Sihuan Pharmaceutical
  • YiChang HEC ChangJiang Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Direct Acting Antivirals Sales Value (2021-2032)
  4. 1.2.2 Global Direct Acting Antivirals Sales Volume (2021-2032)
  5. 1.2.3 Global Direct Acting Antivirals Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Direct Acting Antivirals Market Dynamics
  1. 2.1 Direct Acting Antivirals Industry Trends
  2. 2.2 Direct Acting Antivirals Industry Drivers
  3. 2.3 Direct Acting Antivirals Industry Opportunities and Challenges
  4. 2.4 Direct Acting Antivirals Industry Restraints
3 Direct Acting Antivirals Market by Company
  1. 3.1 Global Direct Acting Antivirals Company Revenue Ranking in 2025
  2. 3.2 Global Direct Acting Antivirals Revenue by Company (2021-2026)
  3. 3.3 Global Direct Acting Antivirals Sales Volume by Company (2021-2026)
  4. 3.4 Global Direct Acting Antivirals Average Price by Company (2021-2026)
  5. 3.5 Global Direct Acting Antivirals Company Ranking (2024-2026)
  6. 3.6 Global Direct Acting Antivirals Company Manufacturing Base and Headquarters
  7. 3.7 Global Direct Acting Antivirals Company Product Type and Application
  8. 3.8 Global Direct Acting Antivirals Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Direct Acting Antivirals Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Direct Acting Antivirals Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Direct Acting Antivirals Market by Type
  1. 4.1 Direct Acting Antivirals Type Introduction
  2. 4.1.1 Pangenotypic
  3. 4.1.2 Genotype-Specific
  4. 4.2 Global Direct Acting Antivirals Sales Volume by Type
  5. 4.2.1 Global Direct Acting Antivirals Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Direct Acting Antivirals Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Direct Acting Antivirals Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Direct Acting Antivirals Sales Value by Type
  9. 4.3.1 Global Direct Acting Antivirals Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Direct Acting Antivirals Sales Value by Type (2021-2032)
  11. 4.3.3 Global Direct Acting Antivirals Sales Value Share by Type (2021-2032)
5 Direct Acting Antivirals Market by Application
  1. 5.1 Direct Acting Antivirals Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Direct Acting Antivirals Sales Volume by Application
  6. 5.2.1 Global Direct Acting Antivirals Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Direct Acting Antivirals Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Direct Acting Antivirals Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Direct Acting Antivirals Sales Value by Application
  10. 5.3.1 Global Direct Acting Antivirals Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Direct Acting Antivirals Sales Value by Application (2021-2032)
  12. 5.3.3 Global Direct Acting Antivirals Sales Value Share by Application (2021-2032)
6 Direct Acting Antivirals Regional Sales and Value Analysis
  1. 6.1 Global Direct Acting Antivirals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Direct Acting Antivirals Sales by Region (2021-2032)
  3. 6.2.1 Global Direct Acting Antivirals Sales by Region: 2021-2026
  4. 6.2.2 Global Direct Acting Antivirals Sales by Region (2027-2032)
  5. 6.3 Global Direct Acting Antivirals Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Direct Acting Antivirals Sales Value by Region (2021-2032)
  7. 6.4.1 Global Direct Acting Antivirals Sales Value by Region: 2021-2026
  8. 6.4.2 Global Direct Acting Antivirals Sales Value by Region (2027-2032)
  9. 6.5 Global Direct Acting Antivirals Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Direct Acting Antivirals Sales Value (2021-2032)
  12. 6.6.2 North America Direct Acting Antivirals Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Direct Acting Antivirals Sales Value (2021-2032)
  15. 6.7.2 Europe Direct Acting Antivirals Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Direct Acting Antivirals Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Direct Acting Antivirals Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Direct Acting Antivirals Sales Value (2021-2032)
  21. 6.9.2 South America Direct Acting Antivirals Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Direct Acting Antivirals Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Direct Acting Antivirals Sales Value Share by Country, 2025 VS 2032
7 Direct Acting Antivirals Country-level Sales and Value Analysis
  1. 7.1 Global Direct Acting Antivirals Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Direct Acting Antivirals Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Direct Acting Antivirals Sales by Country (2021-2032)
  4. 7.3.1 Global Direct Acting Antivirals Sales by Country (2021-2026)
  5. 7.3.2 Global Direct Acting Antivirals Sales by Country (2027-2032)
  6. 7.4 Global Direct Acting Antivirals Sales Value by Country (2021-2032)
  7. 7.4.1 Global Direct Acting Antivirals Sales Value by Country (2021-2026)
  8. 7.4.2 Global Direct Acting Antivirals Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Direct Acting Antivirals Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Direct Acting Antivirals Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Direct Acting Antivirals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Direct Acting Antivirals Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Asegua Therapeutics
  8. 8.2.1 Asegua Therapeutics Company Information
  9. 8.2.2 Asegua Therapeutics Business Overview
  10. 8.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
  12. 8.2.5 Asegua Therapeutics Recent Developments
  13. 8.3 Bristol Myers Squibb
  14. 8.3.1 Bristol Myers Squibb Company Information
  15. 8.3.2 Bristol Myers Squibb Business Overview
  16. 8.3.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
  18. 8.3.5 Bristol Myers Squibb Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Direct Acting Antivirals Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Ascletis Pharma
  32. 8.6.1 Ascletis Pharma Company Information
  33. 8.6.2 Ascletis Pharma Business Overview
  34. 8.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
  36. 8.6.5 Ascletis Pharma Recent Developments
  37. 8.7 Cosunter pharmaceutical
  38. 8.7.1 Cosunter pharmaceutical Company Information
  39. 8.7.2 Cosunter pharmaceutical Business Overview
  40. 8.7.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
  42. 8.7.5 Cosunter pharmaceutical Recent Developments
  43. 8.8 Kawin Technology
  44. 8.8.1 Kawin Technology Company Information
  45. 8.8.2 Kawin Technology Business Overview
  46. 8.8.3 Kawin Technology Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kawin Technology Direct Acting Antivirals Product Portfolio
  48. 8.8.5 Kawin Technology Recent Developments
  49. 8.9 Sanhome Pharmaceutical
  50. 8.9.1 Sanhome Pharmaceutical Company Information
  51. 8.9.2 Sanhome Pharmaceutical Business Overview
  52. 8.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
  54. 8.9.5 Sanhome Pharmaceutical Recent Developments
  55. 8.10 Beijing Sihuan Pharmaceutical
  56. 8.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 8.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 8.10.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
  60. 8.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 8.11 YiChang HEC ChangJiang Pharmaceutical
  62. 8.11.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  63. 8.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  64. 8.11.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
  66. 8.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
  67. 8.12 Chia Tai Tianqing Pharmaceutical
  68. 8.12.1 Chia Tai Tianqing Pharmaceutical Company Information
  69. 8.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
  70. 8.12.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
  72. 8.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Direct Acting Antivirals Value Chain Analysis
  2. 9.1.1 Direct Acting Antivirals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Direct Acting Antivirals Sales Mode & Process
  6. 9.2 Direct Acting Antivirals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Direct Acting Antivirals Distributors
  9. 9.2.3 Direct Acting Antivirals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst